Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Health care stocks were mixed in Wednesday afternoon trading, with the NYSE Health Care Index fractionally higher and the Health Care Select Sector SPDR Fund (XLV) slightly lower. The iShares Biotechn
MT NewswiresApr 17 13:46 ET
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise
NeuroBo Pharmaceuticals (NRBO) said Wednesday the first patient has been dosed in part 1 of its two-part early-stage trial of DA-1726 for the treatment of obesity. The company said part 1 of the study
MT NewswiresApr 17 11:21 ET
Express News | NeuroBo Pharmaceuticals Doses First Patient In Phase 1 Clinical Trial Evaluating DA-1726 For Treatment Of Obesity
Moomoo 24/7Apr 17 08:06 ET
Express News | NeuroBo Pharmaceuticals Inc - First Patient Dosed in Multiple Ascending Dose Part 2 Expected in Q3 of 2024
Moomoo 24/7Apr 17 08:05 ET
Express News | NeuroBo Pharmaceuticals Inc - Top-Line Data Readout From Single Ascending Dose Part 1 Now Expected in Q3 of 2024
Moomoo 24/7Apr 17 08:05 ET
Express News | NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
Moomoo 24/7Apr 17 08:05 ET
Express News | NeuroBo Pharmaceuticals Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing
Moomoo 24/7Apr 12 16:08 ET
Express News | NeuroBo Pharmaceuticals Completes Enrollment Of Part 1 Of Its Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
Moomoo 24/7Apr 1 08:10 ET
NeuroBo Pharmaceuticals GAAP EPS of -$2.46
Seeking AlphaMar 28 15:02 ET
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down
NeuroBo Pharmaceuticals (NRBO) said Wednesday it received the go-ahead to continue its mid-stage clinical trial of DA-1241 without modification, a treatment for metabolic dysfunction-associated steato
MT NewswiresMar 13 12:34 ET
NeuroBo's Phase 2a Trial of DA-124 Proceeds After Safety Review
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NASDAQ:NRBO), a biotech firm specializing in cardiometabolic diseases, announced today that its Phase 2a clinical trial of DA-1241 will continue without changes following a favorable safety review.
Investing.com Mar 13 10:22 ET
KB Financial, BeiGene, Legend Biotech Among Premarket Gainers' Pack
Seeking AlphaMar 13 08:29 ET
Express News | NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
Moomoo 24/7Mar 13 08:04 ET
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today...
PR NewswireMar 13 08:01 ET
NeuroBo Pharmaceuticals Announces Key Leadership Appointment
TipRanksMar 4 07:43 ET
NeuroBo Pharmaceuticals Appoints Marshall H. Woodworth As Chief Financial Officer, Effective March 1, 2024
On March 1, 2024, the Board of Directors (the "Board") of NeuroBo Pharmaceuticals, Inc. (the "Company") appointed Mr. Marshall H. Woodworth, age 66, as the Company's Chief Financial Officer, Principal
BenzingaMar 4 07:39 ET
NeuroBo Stock Jumps 14% on Weight-loss Drug Update
Seeking AlphaFeb 29 09:34 ET
Express News | NeuroBo Pharmaceuticals Receives First Site IRB Approval For Its Phase 1 Clinical Trial Evaluating DA-1726 For Treatment Of Obesity
Moomoo 24/7Feb 29 08:05 ET
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
First Patient Expected to be Randomized in the Second Quarter of 2024 CAMBRIDGE, Mass., Feb. 29, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology comp
PR NewswireFeb 29 08:01 ET
NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook
TipRanksFeb 14 09:02 ET
No Data
No Data